• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

    1.240 UNCHANGED
    Streaming Delayed Price Updated: 11:38 AM EDT, Jun 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,940
    Open 1.250
    Bid (Size) 1.240 (400)
    Ask (Size) 1.250 (300)
    Prev. Close 1.240
    Today's Range 1.240 - 1.265
    52wk Range 1.050 - 3.100
    Shares Outstanding 34,380,971
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
    Via ACCESS Newswire

    Performance

    YTD
    -7.5%
    -7.5%
    1 Month
    -4.6%
    -4.6%
    3 Month
    +8.8%
    +8.8%
    6 Month
    -6.8%
    -6.8%
    1 Year
    -0.8%
    -0.8%

    More News

    Read More
    InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
    Via ACCESS Newswire
    BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
    Via ACCESS Newswire
    MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Closes TELI Acquisition, Secures Global Rights to Telomir-1
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
    Via ACCESS Newswire
    InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
    Via ACCESS Newswire
    BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
    Via ACCESS Newswire
    BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
    Via ACCESS Newswire
    MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Positive Telomir-1 Results In TNBC Zebrafish Xenograft Study
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
    Via ACCESS Newswire
    InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
    Via Investor Brand Network
    News headline image
    Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
    Via ACCESS Newswire
    News headline image
    Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
    Via ACCESS Newswire
    News headline image
    TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death ↗
    Via Stocktwits
    News headline image
    Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
    Via ACCESS Newswire
    News headline image
    Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
    Via ACCESS Newswire
    News headline image
    Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
    Via ACCESS Newswire
    News headline image
    Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
    Via ACCESS Newswire
    News headline image
    Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
    Via ACCESS Newswire

    Frequently Asked Questions

    Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?
    Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market
    What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?
    The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.240
    When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 06/29/26 11:38 AM ET
    What is the market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock is 42.63M
    How many shares of Telomir Pharmaceuticals, Inc. - Common Stock are outstanding?
    Telomir Pharmaceuticals, Inc. - Common Stock has 43M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.